#NASDAQ: CGON
-

CG Oncology Stock Jumps 23.7% After Phase 3 PIVOT-006 Bladder Cancer Data
CG Oncology shares surged to $92 in premarket trading after Phase 3 data showed a 68% reduction in recurrence risk…

CG Oncology shares surged to $92 in premarket trading after Phase 3 data showed a 68% reduction in recurrence risk…